ZVRA (Pharmaceuticals) Stock Valuation & Fair Value Quality business at a reasonable price
ZVRA (Pharmaceuticals) trades at a blended P/E of 8.4, about 27% above its historical normal valuation, with a forward growth estimate of 11.2% and a PEG of 0.75. Analysts' one-year estimates have been hit 10% of the time.
Valuation flags
- Overvalued by 27%
Frequently asked questions
Is ZVRA overvalued?
At a blended P/E of 8.4 versus its historical normal P/E of 6.6, ZVRA trades about 27% above its typical valuation, with a PEG of 0.75 on 11.2% forward growth. tickerseer currently rates it quality business at a reasonable price.
What is ZVRA's fair value and PEG?
ZVRA trades at a blended P/E of 8.4 against a historical normal P/E of 6.6, a PEG of 0.75, and a forward growth estimate of 11.2%.
Has tickerseer's rating of ZVRA changed?
tickerseer's rating has been quality business at a reasonable price since 2026-07-31.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.